drugset
drugset / Trial / NCT05429749

Intravenous Iron Supplement to Prevent Postoperative Delirium After Hip Fracture Surgery

NCT05429749 ↗

Phase 4 Unknown 264 enrolled Seoul National University Bundang Hospital JW Pharmaceutical · collab
Non-randomizedParallel-groupOpen-labelPrevention

Summary

This is a clinical trial to evaluate the effect of intravenous iron supplement with Ferinject (Ferric Carboxymaltose) in preventing postoperative delirium after hip fracture surgery.

Timeline

Start
2020-07-30
Primary completion
2023-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric carboxymaltose Other / unclassified 1000 mg Intravenous

Indications

No indication recorded.